弥漫性大B细胞淋巴瘤是亚洲人最常见的淋巴肿瘤亚型，经过R-CHOP方案治疗后仍有相当一部分患者表现为难治或复发。弥漫性大B细胞淋巴瘤的常见致病信号通路有B细胞受体、Toll样受体4/髓样分子因子88/核因子-κB、磷脂酰肌醇3-激酶/蛋白激酶B信号通路，靶向药物包括Bruton酪氨酸激酶抑制剂、来那度胺、硼替佐米、凋亡蛋白抑制剂抑制剂、磷脂酰肌醇3-激酶抑制剂、蛋白激酶B抑制剂、哺乳动物雷帕霉素靶蛋白抑制剂。阐述了弥漫性大B细胞淋巴瘤中常见致病信号通路及其遗传学改变，并总结了相关通路常见的靶向药物的研究进展。

Diffuse large B cell lymphoma is the most common subtype of lymphoma in Asians. A significant proportion of patients remain refractory or relapsed after R-CHOP regimen. The common pathogenic signaling pathways of diffuse large B-cell lymphoma include B cell receptor (BCR), TLR-MYD88-NF-κB, and PI3K/Akt signaling pathway. Targeted drugs include BTK inhibitors, lenalidomide, bortezomib, IAP inhibitors, PI3K inhibitors, Akt inhibitors, and mTOR inhibitor. This article describes the common pathogenic signaling pathways and their genetic changes in diffuse large B-cell lymphoma, and summarizes the research progress on drugs targeted related pathways.

R979.1

贵州省科技计划项目(黔科合支撑[2019]2788号)